Literature DB >> 27766226

NF-Kβ Activation in U266 Cells on Mesenchymal Stem Cells.

Sara Zahedi1, Karim Shamsasenjan1, Aliakbar Movassaghpour1, Parvin Akbarzadehlaleh2.   

Abstract

Purpose: Mesenchymal Stem Cells (MSCs) are one of the essential members of Bone Marrow (BM) microenvironment and the cells affect normal and malignant cells in BM milieu. One of the most important hematological malignancies is Multiple Myeloma (MM). Numerous studies reported various effects of MSCs on myeloma cells. MSCs initiate various signaling pathways in myeloma cells, particularly NF-kβ. NF-kβ signaling pathway plays pivotal role in the survival, proliferation and resistance of myeloma cells to the anticancer drugs, therefore this pathway can be said to be a vital target for cancer therapy. This study examined the relationship between U266 cells and MSCs.
Methods: U266 cells were cultured with Umbilical Cord Blood derived-MSCs (UCB-MSCs) and Conditioned Medium (C.M). Effect of UCB-MSCs and C.M on proliferation rate and CD54 expression of U266 cells were examined with MTT assay and Flowcytometry respectively. Furthermore, expression of CXCL1, PECAM-1, JUNB, CCL2, CD44, CCL4, IL-6, and IL-8 were analyzed by Real Time-PCR (RT-PCR). Moreover, status of p65 protein in NF-kβ pathway assessed by western blotting.
Results: Our findings confirm that UCB-MSCs support U266 cells proliferation and they increase CD54 expression. In addition, we demonstrate that UCB-MSCs alter the expression of CCL4, IL-6, IL-8, CXCL1 and the levels of phosphorylated p65 in U266 cells.
Conclusion: Our study provides a novel sight to the role of MSCs in the activation of NF-kβ signaling pathway. So, NF-kβ signaling pathway will be targeted in future therapies against MM.

Entities:  

Keywords:  CD54; IL-6; Mesenchymal Stem Cell; NF-kβ signaling pathway; U266 cell line; p65

Year:  2016        PMID: 27766226      PMCID: PMC5071805          DOI: 10.15171/apb.2016.054

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  46 in total

1.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 2.  Bone markers in multiple myeloma.

Authors:  Ulrike Heider; Claudia Fleissner; Ivana Zavrski; Martin Kaiser; Monica Hecht; Christian Jakob; Orhan Sezer
Journal:  Eur J Cancer       Date:  2006-06-09       Impact factor: 9.162

3.  p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner.

Authors:  Vassilis G Gorgoulis; Panayotis Zacharatos; Athanassios Kotsinas; Dimitris Kletsas; George Mariatos; Vassilis Zoumpourlis; Kevin M Ryan; Christos Kittas; Athanasios G Papavassiliou
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

4.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

5.  Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.

Authors:  C S Debes-Marun; G W Dewald; S Bryant; E Picken; R Santana-Dávila; N González-Paz; J M Winkler; R A Kyle; M A Gertz; T E Witzig; A Dispenzieri; M Q Lacy; S V Rajkumar; J A Lust; P R Greipp; R Fonseca
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

7.  IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide.

Authors:  Fan Yang; Eric Tang; Kunliang Guan; Cun-Yu Wang
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

Review 8.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

9.  Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.

Authors:  Yulia N Demchenko; Leslie A Brents; Zhihong Li; Leif P Bergsagel; Lawrence R McGee; Michael W Kuehl
Journal:  Oncotarget       Date:  2014-06-30

10.  Nonsecretory multiple myeloma.

Authors:  Seshikanth Middela; Prakash Kanse
Journal:  Indian J Orthop       Date:  2009-10       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.